title: Wwox expression may predict benefit from adjuvant tamoxifen in randomized             breast cancer patients.
abstract: Reduced or absent Wwox expression has recently been associated with tamoxifen             resistance in breast cancer and has also been proposed as a candidate predictive             marker for treatment. We aimed to investigate the correlation of Wwox expression             with the outcome of tamoxifen treatment by examining tissues from 912 randomized             breast cancer patients. Paraffin-embedded tissues from patient tumors were arranged             on tissue microarray, and Wwox protein was stained using immunohistochemistry.             After microscopic examination, the results were analyzed with Cox regression,             Kaplan-Meier survival curves and the log-rank test. In the group of cases having             a tumor absent for Wwox expression, there was no difference in recurrence-free             survival between treated and untreated patients (P=0.81). For treated cases with             a tumor expressing moderate or strong Wwox protein, recurrence-free survival was             improved (P=0.001 and P=0.003, respectively). The test for interaction between             Wwox and treatment response demonstrated a decreased risk of recurrence for treated             patients with a moderate or strong Wwox expression (HR=0.31, 95% CI 0.10-0.98             and HR=0.28, 95% CI 0.08-0.97, respectively). Our results indicate that patients             with high expression of Wwox may gain more benefit from treatment with tamoxifen.
authors: School of Health and Medical Sciences, Örebro University, SE-70182 Örebro, Sweden. anna.gothlin-eremo@oru.se
authors: Anna
authors: A
authors: Göthlin Eremo
authors: Pia
authors: P
authors: Wegman
authors: Olle
authors: O
authors: Stål
authors: Bo
authors: B
authors: Nordenskjöld
authors: Tommy
authors: T
authors: Fornander
authors: Sten
authors: S
authors: Wingren
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D053208:Kaplan-Meier Estimate; D010088:Oxidoreductases / Q000235:genetics* / Q000378:metabolism; D011379:Prognosis; D013629:Tamoxifen / Q000008:administration & dosage*; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000378:metabolism; D000074584:WW Domain-Containing Oxidoreductase
chemical_list: D018931:Antineoplastic Agents, Hormonal; D025521:Tumor Suppressor Proteins; D013629:Tamoxifen; D010088:Oxidoreductases; D000074584:WW Domain-Containing Oxidoreductase; C486071:WWOX protein, human